Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,047 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Injection Clear all
Completed Phase 2 Interventional Results available

The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy

NCT01710332
View directory record Official record
Conditions
Central Serous Chorioretinopathy
Interventions
Intravitreal Aflibercept Injection
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Sep 3, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

NCT01011049
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine USP Trivalent Types A and B
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
44
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 3, 2026, 10:05 PM EDT
Not listed Phase 2 Interventional

Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain

NCT05470608
View directory record Official record
Conditions
Osteoarthritis, Knee Pain
Interventions
SL-1002, Placebo
Drug
Lead sponsor
Saol Therapeutics Inc
Industry
Eligibility
35 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Greenwood Village, Colorado • Washington D.C., District of Columbia • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 3, 2026, 10:05 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Treatment of Facial Flushing With Botulinum Toxin A Injections

NCT02216838
View directory record Official record
Conditions
Facial Flushing
Interventions
botulinum toxin A, Saline Control
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 3, 2026, 10:05 PM EDT
Completed Phase 4 Interventional

Biomarkers of Injectable Extended Release Naltrexone Treatment

NCT02324725
View directory record Official record
Conditions
Heroin Dependence, Opioid Dependence
Interventions
Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Sep 3, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

NCT01490450
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Placebo matching BMS-945429, BMS-945429
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
San Diego, California • Denver, Colorado • Trumbull, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 3, 2026, 10:05 PM EDT
Completed Phase 1 Interventional Results available

Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)

NCT01707225
View directory record Official record
Conditions
Gastrointestinal Bleeding
Interventions
Octreotide LAR Depot
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Sep 3, 2026, 10:05 PM EDT
Completed Phase 3 Interventional

Cognitive Behavioral Therapy Combined With Antidepressants to Reduce HIV Risk and Drug Relapse Among Depressed Intravenous Drug Users

NCT00183768
View directory record Official record
Conditions
HIV Infections, Depression, Substance-Related Disorders
Interventions
Cognitive Behavioral Therapy, Psychopharmacology
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Sep 3, 2026, 10:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

NCT03379168
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline
Device · Drug
Lead sponsor
Dustin L. Richter, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 3, 2026, 10:05 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

L-Menthol Injection as a Novel Technique During Colonoscopy

NCT02588248
View directory record Official record
Conditions
Colonic Polyps, Colon Cancer
Interventions
Peppermint Oil, Placebo
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 3, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

NCT03378076
View directory record Official record
Conditions
Bilateral Knee Osteoarthritis
Interventions
FX006 32 mg, TAcs 40 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Torrance, California • Rochester, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 3, 2026, 10:05 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

NCT06672055
View directory record Official record
Conditions
SARS-CoV2, COVID-19
Interventions
VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years and older
Enrollment
5,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
145
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 3, 2026, 10:05 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

NCT07232004
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-547, ABBV-547 Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Bryant, Arkansas • Anaheim, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 3, 2026, 10:05 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Pharmacokinetics of a Dexamethasone Iontophoretic Patch to a Dexamethasone Injection

NCT00895076
View directory record Official record
Conditions
Lateral Epicondylitis (Tennis Elbow)
Interventions
dexamethasone
Drug
Lead sponsor
Travanti Pharma Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 6, 2009 · Synced Sep 3, 2026, 10:05 PM EDT
Terminated Phase 1 Interventional

Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver

NCT00301106
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
adenovirus-mediated human interleukin-12
Biological
Lead sponsor
Max Sung
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 3, 2026, 10:05 PM EDT
Terminated Phase 3 Interventional Results available

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study

NCT01237340
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
Saizen®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
US Medical Information, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 3, 2026, 10:05 PM EDT
Completed Phase 4 Interventional Results available

Easypod United States User Trial

NCT00689260
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
easypod
Device
Lead sponsor
EMD Serono
Industry
Eligibility
10 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 3, 2026, 10:05 PM EDT
Withdrawn Phase 1 Interventional

Comparison of Distraction Methods for Pain Relief of Trigger Finger Injection

NCT03445780
View directory record Official record
Conditions
Trigger Finger
Interventions
Ethyl chloride spray, Pinching, No Site of Procedure
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 3, 2026, 10:05 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

NCT02055274
View directory record Official record
Conditions
Parkinson's Disease
Interventions
LY03003, Neupro
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Long Beach, California • Orlando, Florida • Douglasville, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 3, 2026, 10:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome

NCT07135050
View directory record Official record
Conditions
Pitt Hopkins Syndrome
Interventions
MZ-1866
Genetic
Lead sponsor
Mahzi Therapeutics
Industry
Eligibility
2 Years to 25 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Oakland, California • Aurora, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 3, 2026, 10:05 PM EDT
Recruiting Phase 2 Interventional

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

NCT06223659
View directory record Official record
Conditions
Cutaneous Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma
Interventions
Eutectic Mixture of Local Anesthetics, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 3, 2026, 10:05 PM EDT
Completed Phase 1 Interventional

A Study of RG-012 in Subjects With Alport Syndrome

NCT03373786
View directory record Official record
Conditions
Alport Syndrome
Interventions
RG012
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
La Mesa, California • Los Angeles, California • Riverside, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 3, 2026, 10:05 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results

NCT01657669
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Intravitreal Aflibercept injection
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
50 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
3
States / cities
St Louis, Missouri • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Sep 3, 2026, 10:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects

NCT01992380
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Newport Beach, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 6, 2020 · Synced Sep 3, 2026, 10:05 PM EDT